» Articles » PMID: 34406569

Long-term Clinical Observation of Patients with Acute and Chronic Complete Spinal Cord Injury After Transplantation of NeuroRegen Scaffold

Abstract

Spinal cord injury (SCI) often results in an inhibitory environment at the injury site. In our previous studies, transplantation of a scaffold combined with stem cells was proven to induce neural regeneration in animal models of complete SCI. Based on these preclinical studies, collagen scaffolds loaded with the patients' own bone marrow mononuclear cells or human umbilical cord mesenchymal stem cells were transplanted into SCI patients. Fifteen patients with acute complete SCI and 51 patients with chronic complete SCI were enrolled and followed up for 2 to 5 years. No serious adverse events related to functional scaffold transplantation were observed. Among the patients with acute SCI, five patients achieved expansion of their sensory positions and six patients recovered sensation in the bowel or bladder. Additionally, four patients regained voluntary walking ability accompanied by reconnection of neural signal transduction. Among patients with chronic SCI, 16 patients achieved expansion of their sensation level and 30 patients experienced enhanced reflexive defecation sensation or increased skin sweating below the injury site. Nearly half of the patients with chronic cervical SCI developed enhanced finger activity. These long-term follow-up results suggest that functional scaffold transplantation may represent a feasible treatment for patients with complete SCI.

Citing Articles

Biomaterial scaffold stiffness influences the foreign body reaction, tissue stiffness, angiogenesis and neuroregeneration in spinal cord injury.

Zheng Y, Nutzl M, Schackel T, Chen J, Weidner N, Muller R Bioact Mater. 2025; 46:134-149.

PMID: 39760066 PMC: 11700269. DOI: 10.1016/j.bioactmat.2024.12.006.


Injectable alginate chitosan hydrogel as a promising bioengineered therapy for acute spinal cord injury.

Saadinam F, Azami M, Pedram M, Sadeghinezhad J, Fakhr M, Salimi A Sci Rep. 2024; 14(1):26747.

PMID: 39500959 PMC: 11538431. DOI: 10.1038/s41598-024-77995-2.


Promotion of nerve regeneration and motor function recovery in SCI rats using LOCAS-iPSCs-NSCs.

Xu G, Ge R, Zhang C, Zhao Z, Han L, Zhang W Stem Cell Res Ther. 2024; 15(1):376.

PMID: 39444002 PMC: 11515548. DOI: 10.1186/s13287-024-03999-4.


Regional biomechanical characterization of the spinal cord tissue: dynamic mechanical response.

Jin C, Yu J, Li R, Ye X Front Bioeng Biotechnol. 2024; 12:1439323.

PMID: 39219623 PMC: 11361947. DOI: 10.3389/fbioe.2024.1439323.


Functional biomaterials for modulating the dysfunctional pathological microenvironment of spinal cord injury.

Ma D, Fu C, Li F, Ruan R, Lin Y, Li X Bioact Mater. 2024; 39:521-543.

PMID: 38883317 PMC: 11179178. DOI: 10.1016/j.bioactmat.2024.04.015.


References
1.
Adams M, Hicks A . Spasticity after spinal cord injury. Spinal Cord. 2005; 43(10):577-86. DOI: 10.1038/sj.sc.3101757. View

2.
Assinck P, Duncan G, Hilton B, Plemel J, Tetzlaff W . Cell transplantation therapy for spinal cord injury. Nat Neurosci. 2017; 20(5):637-647. DOI: 10.1038/nn.4541. View

3.
Bartlett R, Burley S, Ip M, Phillips J, Choi D . Cell Therapies for Spinal Cord Injury: Trends and Challenges of Current Clinical Trials. Neurosurgery. 2020; 87(4):E456-E472. DOI: 10.1093/neuros/nyaa149. View

4.
Cyranoski D . Japan's approval of stem-cell treatment for spinal-cord injury concerns scientists. Nature. 2019; 565(7741):544-545. DOI: 10.1038/d41586-019-00178-x. View

5.
Ditunno J, Little J, Tessler A, Burns A . Spinal shock revisited: a four-phase model. Spinal Cord. 2004; 42(7):383-95. DOI: 10.1038/sj.sc.3101603. View